Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

What happened: Zymeworks entered an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks will run the Phase 1a monotherapy trial with Roche, which will fund it and handle later global development and commercialization. Key numbers: Why it matters: Zymeworks said the deal lets it advance ZW209 through initial clinical development while sharing development risk and preserving participation in future success. Roche said ZW209 complements its efforts to develop new treatment options for people living with lung cancer.

Zymeworks entered an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks will run the Phase 1a monotherapy trial with Roche, which will fund it and handle later global development and commercialization.

Zymeworks said the deal lets it advance ZW209 through initial clinical development while sharing development risk and preserving participation in future success. Roche said ZW209 complements its efforts to develop new treatment options for people living with lung cancer.